Roferon A (Hoffmann-La Roche Inc)
Roferon A (Hoffmann-La Roche Inc) Brand names, Roferon A (Hoffmann-La Roche Inc) Analogs
Roferon A (Hoffmann-La Roche Inc) Brand Names Mixture
- No information avaliable
Roferon A (Hoffmann-La Roche Inc) Chemical_Formula
C860H1353N227O255S9
Roferon A (Hoffmann-La Roche Inc) RX_link
http://www.drugs.com/cons/Roferon_A.html
Roferon A (Hoffmann-La Roche Inc) fda sheet
Roferon A (Hoffmann-La Roche Inc) msds (material safety sheet)
Roferon A (Hoffmann-La Roche Inc) Synthesis Reference
No information avaliable
Roferon A (Hoffmann-La Roche Inc) Molecular Weight
19241.1
Roferon A (Hoffmann-La Roche Inc) Melting Point
No information avaliable
Roferon A (Hoffmann-La Roche Inc) H2O Solubility
100 mg/ml
Roferon A (Hoffmann-La Roche Inc) State
Liquid
Roferon A (Hoffmann-La Roche Inc) LogP
-0.336
Roferon A (Hoffmann-La Roche Inc) Dosage Forms
Solution
Roferon A (Hoffmann-La Roche Inc) Indication
For treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia
Roferon A (Hoffmann-La Roche Inc) Pharmacology
Upregulates the expression of MHC I proteins, allowing for increased presentation of peptides derived from viral antigens. This enhances the activation of CD8+ T cells that are the precursors for cytotoxic T lymphocytes (CTLs) and makes the macrophage a better target for CTL-mediated killing. Interferon alpha also induce the synthesis of several key antiviral mediators, including 2'-5' oligoadenylate synthetase (2'-5' A synthetase) and protein kinase R.
Roferon A (Hoffmann-La Roche Inc) Absorption
No information avaliable
Roferon A (Hoffmann-La Roche Inc) side effects and Toxicity
No information avaliable
Roferon A (Hoffmann-La Roche Inc) Patient Information
No information avaliable
Roferon A (Hoffmann-La Roche Inc) Organisms Affected
No information avaliable
